SRDX - Surmodics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.20
+0.14 (+0.36%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close39.06
Open39.20
Bid38.88 x 1100
Ask39.71 x 800
Day's Range39.20 - 39.20
52 Week Range38.06 - 82.35
Volume371
Avg. Volume117,357
Market Cap528.749M
Beta (3Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateNov 14, 2017 - Nov 20, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.00
Trade prices are not sourced from all markets
  • Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
    Zacks26 days ago

    Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

    Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

  • Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?

    Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.

  • Hedge Funds Have Never Been More Bullish On SurModics, Inc. (SRDX)
    Insider Monkeylast month

    Hedge Funds Have Never Been More Bullish On SurModics, Inc. (SRDX)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?
    Simply Wall St.last month

    When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?

    Surmodics, Inc. (NASDAQ:SRDX), which is in the medical equipment business, and is based in United States, received a...

  • Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
    Zacks2 months ago

    Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller

    Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller

  • Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?
    Zacks2 months ago

    Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?

    SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • New Analyst Coverage Puts Spotlight on These 5 Stocks
    Zacks2 months ago

    New Analyst Coverage Puts Spotlight on These 5 Stocks

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • Business Wire2 months ago

    Surmodics to Present at Jefferies Healthcare Conference

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2019 Healthcare Conference in New York City on Tuesday, June 4, 2019, at 10:30 a.m. ET (9:30 a.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and clicking on the webcast icon.

  • Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
    Zacks2 months ago

    Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

    Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

  • 5 Stocks to Keep an Eye on as Analysts Initiate Coverage
    Zacks2 months ago

    5 Stocks to Keep an Eye on as Analysts Initiate Coverage

    More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • Did Surmodics, Inc. (NASDAQ:SRDX) Insiders Sell Shares?
    Simply Wall St.2 months ago

    Did Surmodics, Inc. (NASDAQ:SRDX) Insiders Sell Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Hedge Funds Have Never Been This Bullish On SurModics, Inc. (SRDX)
    Insider Monkey2 months ago

    Hedge Funds Have Never Been This Bullish On SurModics, Inc. (SRDX)

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
    Zacks3 months ago

    Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

    Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SRDX earnings conference call or presentation 1-May-19 9:00pm GMT

    Q2 2019 Surmodics Inc Earnings Call

  • SurModics (SRDX) Q2 2019 Earnings Call Transcript
    Motley Fool3 months ago

    SurModics (SRDX) Q2 2019 Earnings Call Transcript

    SRDX earnings call for the period ending March 31, 2019.

  • Associated Press3 months ago

    SurModics: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Eden Prairie, Minnesota-based company said it had net income of 9 cents. Earnings, adjusted for non-recurring gains, were 7 cents per share. The drug delivery technology company ...

  • Business Wire3 months ago

    Surmodics Reports Second Quarter Fiscal 2019 Results

    Updates Fiscal 2019 Guidance

  • Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline
    Zacks3 months ago

    Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

    SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire3 months ago

    Surmodics to Webcast Second Quarter Fiscal 2019 Earnings Conference Call on May 1

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2019 conference call on Wednesday, May 1, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the second quarter fiscal 2019 financial results and accomplishments.

  • Business Wire3 months ago

    Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ guide sheath. “Surmodics continues to make progress in the development of clinically important and innovative technologies,” said Gary Maharaj, Surmodics President and CEO. Radial artery access has been widely adopted for use in coronary procedures where devices have been developed to accommodate that need.

  • Business Wire3 months ago

    Surmodics Provides Update Regarding TRANSCEND Clinical Trial

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB), was temporarily paused following the March 15 publication of a Food & Drug Administration (FDA) letter to physicians.

  • Shareholders Are Thrilled That The Surmodics (NASDAQ:SRDX) Share Price Increased 132%
    Simply Wall St.3 months ago

    Shareholders Are Thrilled That The Surmodics (NASDAQ:SRDX) Share Price Increased 132%

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For exam...

  • Business Wire4 months ago

    Surmodics to Present at Needham Healthcare Conference

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, at 1:30 p.m. ET (12:30 p.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com, clicking on the webcast link and, on the conference's registration page, completing the required fields to register.

  • Why An FDA Probe Is Rocking The Boat For These Medical Device Makers
    Investor's Business Daily4 months ago

    Why An FDA Probe Is Rocking The Boat For These Medical Device Makers

    A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.